Health & Fitness
Health and Fitness
Health and Fitness 
Tue, March 20, 2012
Mon, March 19, 2012
Tengion to Host Conference Call to Provide a Business Update and Report Fourth Quarter 2011 Financial Results on March 26, 2012
Tengion to Host Conference Call to Provide a Business Update and Report... -- WINSTON-SALEM, N.C., March 19, 2012 /PRNewswire/ --
Tengion to Host Conference Call to Provide a Business Update and Report Fourth Quarter 2011 Financial Results on March 26, 2012
WINSTON-SALEM, N.C., March 19, 2012 /PRNewswire/ -- Tengion, Inc. (NASDAQ: [ TNGN ]), a leader in regenerative medicine, today announced it will host a conference call and live audio webcast on Monday, March 26, 2012, at 5:00 p.m. EDT to provide a business update and discuss its fourth quarter 2011 financial results.
To participate in the call, please dial 1-800-638-4930 (domestic) or 1-617-614-3944 (international) and reference access code 34844557.
The conference call can be accessed from the [ Investors ] section of the Company's website or directly at [ http://edge.media-server.com/m/p/o4v89uyi/lan/en ]. The webcast will also be archived on the website.
About Tengion
Tengion, a clinical-stage regenerative medicine company, is focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ. Using its Organ Regeneration Platform™, the Company creates neo-organs using a patient's own cells, or autologous cells. Tengion's proprietary product candidates harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues. The Company's product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications. An initial clinical trial is ongoing for the Company's lead product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company's lead preclinical candidate is the Neo-Kidney Augment™, which is designed to prevent or delay dialysis by increasing renal function in patients with advanced chronic kidney disease. Tengion has worldwide rights to its product candidates.
SOURCE Tengion, Inc.
[ Back to top ] RELATED LINKS
[ http://www.tengion.com ]